TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37611174

Group type: EXPERIMENTAL
Intervention: ASICA app for monthly total-skin self-examinations (TSSE)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Qualitative study of barriers and facilitators to TSSE adherence using the app
Number of subjects: 14
Study: 37611246

Group type: EXPERIMENTAL
Intervention: Berberine 500 mg TID for 20 weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 37611283

Group type: EXPERIMENTAL
Intervention: Midline Catheter (MC) with differing antithrombotic properties
Number of subjects: 191
Study: 37611354

Group type: EXPERIMENTAL
Intervention: Tailored self-care intervention
Number of subjects: 139

Group type: COMPARATOR
Intervention: Cognitive behavior therapy
Number of subjects: 139
Study: 37611527

Group type: EXPERIMENTAL
Intervention: Estradiol and Progesterone (EP)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 37611731

Group type: EXPERIMENTAL
Intervention: Zero Gravity (ZG) system
Number of subjects: 71

Group type: COMPARATOR
Intervention: Conventional radiation protection
Number of subjects: 71
Study: 37611799

Group type: EXPERIMENTAL
Intervention: Lung Chemoembolization
Number of subjects: 0
Study: 37611857

Group type: EXPERIMENTAL
Intervention: PPG (pullback pressure gradient) assessment pre-PCI
Number of subjects: 982
Study: 37612008

Group type: EXPERIMENTAL
Intervention: HM3 LVAD
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Preimplant characteristics (elevated blood urea nitrogen, prior coronary artery bypass graft or valve procedure) and postimplant characteristics (hemocompatibility-related adverse events, ventricular arrhythmias, estimated glomerular filtration rate <60 mL/min/1.73 m²)
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Patients without identified predictors of risk
Number of subjects: 485
Study: 37612103

Group type: EXPERIMENTAL
Intervention: Dementia care management intervention
Number of subjects: 0
Study: 37612102

Group type: EXPERIMENTAL
Intervention: Oral supplementation for patients with severe vitamin C depletion
Number of subjects: 385
Study: 37612109

Group type: EXPERIMENTAL
Intervention: IDMS-MDRD equation
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: KOR-CKD-EPI
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: IDMS-MDRD-GFR
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: CKD-EPI (2021)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: KOR-IDMS-MDRD
Number of subjects: 211
Study: 37612114

Group type: EXPERIMENTAL
Intervention: Dual hormone fully closed loop (DHFCL)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care (HCL or treatment with multiple daily insulin injections + FGM/CGM)
Number of subjects: 240
Study: 37612115

Group type: EXPERIMENTAL
Intervention: 30 mg CBN
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 300 mg CBN
Number of subjects: 20

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 20
Study: 37612192

Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation (ASV)
Number of subjects: 503

Group type: COMPARATOR
Intervention: Control group (patients who refused or stopped ASV before three months follow-up)
Number of subjects: 503
Study: 37612223

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors
Number of subjects: 10
Study: 37612250

Group type: EXPERIMENTAL
Intervention: Wearable photoplethysmography-based monitor
Number of subjects: 145

Group type: COMPARATOR
Intervention: Capnograph
Number of subjects: 145

Group type: COMPARATOR
Intervention: Ventilator monitor
Number of subjects: 145
Study: 37612300

Group type: EXPERIMENTAL
Intervention: mRNA-1273.214 (50-µg)
Number of subjects: 813

Group type: COMPARATOR
Intervention: mRNA-1273 (50-µg)
Number of subjects: 813
Study: 37612310

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 humoral and cellular immunity
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 immunity after two vaccine doses
Number of subjects: 86
Study: 37612450

Group type: EXPERIMENTAL
Intervention: Standardized trauma intake form (TIF)
Number of subjects: 4077
Study: 37612529

Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 158
Study: 37612534

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Battle field auricular acupuncture (BFAA)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA) and Battle field auricular acupuncture (BFAA)
Number of subjects: 165
Study: 37612608

Group type: EXPERIMENTAL
Intervention: IPF patients with antifibrotic therapy at enrolment
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: IPF patients who are male or white
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Overall cohort of IPF patients
Number of subjects: 1002
Study: 37612610

Group type: EXPERIMENTAL
Intervention: Biopsy combined with same-session MR-guided LITT therapy followed by CRT
Number of subjects: 238

Group type: COMPARATOR
Intervention: Biopsy followed by CRT (current standard of care)
Number of subjects: 238
Study: 37612621

Group type: EXPERIMENTAL
Intervention: Biweekly single-dose actinomycin D (1.25 mg/m² IV pulse)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multiday methotrexate therapy
Number of subjects: 0
Study: 37612631

Group type: EXPERIMENTAL
Intervention: 2016 U.K. National Institute of Health and Care Excellence guideline-determined diagnostic strategy
Number of subjects: 800

Group type: COMPARATOR
Intervention: 2019 European Society of Cardiology guideline-determined diagnostic strategy
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Both strategies
Number of subjects: 800
Study: 37612651

Group type: EXPERIMENTAL
Intervention: SAVR
Number of subjects: 80

Group type: COMPARATOR
Intervention: TAVI
Number of subjects: 80
Study: 37612654

Group type: COMPARATOR
Intervention: Nurse-led patient education program (Mouth Education Program, MEP)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Locally applied pilocarpine drops
Number of subjects: 348
Study: 37612687

Group type: EXPERIMENTAL
Intervention: Body Project intervention (BP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Healthy Weight intervention (HW)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Waiting-list control group (WLCG)
Number of subjects: 40
Study: 37612695

Group type: EXPERIMENTAL
Intervention: ePIPARI - web-based follow-up tool
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinical follow-up
Number of subjects: 0
Study: 37612698

Group type: EXPERIMENTAL
Intervention: Take home naloxone (THN) from participating harm reduction and drug treatment sites
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Concentrated nasal naloxone, Nyxoid
Number of subjects: 600
Study: 37612723

Group type: EXPERIMENTAL
Intervention: M-ROSE combined with mNGS
Number of subjects: 166

Group type: COMPARATOR
Intervention: mNGS only
Number of subjects: 166
Study: 37612774

Group type: EXPERIMENTAL
Intervention: Wearable device monitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical scores and blood analyses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subjective disease development and quality of life assessments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Usability of the smartwatch
Number of subjects: 0
Study: 37612879

Group type: EXPERIMENTAL
Intervention: injectable platelet-rich fibrin (i-PRF)
Number of subjects: 23

Group type: COMPARATOR
Intervention: platelet-rich plasma (PRP)
Number of subjects: 23
Study: 37614066

Group type: EXPERIMENTAL
Intervention: Immediate IUD placement within 48 hours after medical abortion
Number of subjects: 240

Group type: COMPARATOR
Intervention: Delayed IUD placement 2-4 weeks after medical abortion
Number of subjects: 240
Study: 37614129

Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Contingency management
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Matrix group model
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: SMS text messaging
Number of subjects: 42
Study: 37614541

Group type: EXPERIMENTAL
Intervention: Tafolecimab 450 mg every 4 weeks (Q4W)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303
Study: 37614548

Group type: EXPERIMENTAL
Intervention: Adherence to ABC pathway
Number of subjects: 4013

Group type: COMPARATOR
Intervention: Non-adherence to ABC pathway
Number of subjects: 4013
Study: 37614821

Group type: EXPERIMENTAL
Intervention: Intracerebroventricular CLN5 gene therapy
Number of subjects: 0
Study: 37614943

Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy after 3 months of DAPT
Number of subjects: 652

Group type: COMPARATOR
Intervention: Ticagrelor-based DAPT for 12 months
Number of subjects: 652
Study: 37615254

Group type: EXPERIMENTAL
Intervention: Giant mitochondria or megamitochondria presence in liver parenchymal cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presence of highly organised crystal-like intramitochondrial inclusions
Number of subjects: 0
Study: 37615485

Group type: EXPERIMENTAL
Intervention: Cyclic fasting-mimicking diet (FMD) with carboplatin-gemcitabine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Carboplatin-based chemotherapy alone
Number of subjects: 14
Study: 37615566

Group type: EXPERIMENTAL
Intervention: Maternal SARS-CoV-2 Vaccination
Number of subjects: 0
Study: 37615581

Group type: EXPERIMENTAL
Intervention: Vitil-IA algorithm for assessing depigmentation on standardized facial ultraviolet pictures.
Number of subjects: 22

Group type: COMPARATOR
Intervention: F-VASI score
Number of subjects: 22

Group type: COMPARATOR
Intervention: Homogeneous depigmentation assessment
Number of subjects: 22

Group type: COMPARATOR
Intervention: Heterogeneous depigmentation assessment
Number of subjects: 22
Study: 37615836

Group type: EXPERIMENTAL
Intervention: Peak Pruritus Numerical Rating Scale (PP NRS)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Nemolizumab (drug treatment)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 21
Study: 37615850

Group type: EXPERIMENTAL
Intervention: Ramipril 2.5 mg daily
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study: 37615989

Group type: EXPERIMENTAL
Intervention: TLC with MTM (intensive telephone coaching and combination nicotine replacement therapy for 1 year with at least monthly contact, plus pharmacist-referral for prescription medications)
Number of subjects: 636

Group type: COMPARATOR
Intervention: TLC (intensive telephone coaching and combination nicotine replacement therapy for 1 year with at least monthly contact)
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Quarterly TLC (intensity of TLC decreased to quarterly contact)
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Overall TLC groups
Number of subjects: 636
Study: 37616032

Group type: EXPERIMENTAL
Intervention: NiteCAPP CARES (web-based cognitive behavioral therapy for insomnia)
Number of subjects: 5
Study: 37616070

Group type: EXPERIMENTAL
Intervention: P. vivax infection
Number of subjects: 0

Group type: COMPARATOR
Intervention: P. falciparum infection
Number of subjects: 0
Study: 37616127

Group type: EXPERIMENTAL
Intervention: Central reading of endoscopy (CR1 and CR2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Local readers (LR) vs Central readers (CR1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Local readers (LR) vs Central readers (CR2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Consensus reads (ConCR) with LR and CR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CR1 vs CR2 without consensus reads
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CR1 vs CR2 with consensus reads
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Consensus-based approaches
Number of subjects: 0
Study: 37616177

Group type: EXPERIMENTAL
Intervention: Excisional hemorrhoidectomy
Number of subjects: 1681

Group type: COMPARATOR
Intervention: Hemorrhoidal artery ligation
Number of subjects: 1681

Group type: EXPERIMENTAL
Intervention: Excisional hemorrhoidectomy with new devices
Number of subjects: 1681
Study: 37616221

Group type: EXPERIMENTAL
Intervention: Quadrivalent Influenza HA vaccine (QIV)
Number of subjects: 540

Group type: COMPARATOR
Intervention: Trivalent Influenza HA vaccine (TIV)
Number of subjects: 540
Study: 37616265

Group type: EXPERIMENTAL
Intervention: Chronic tinnitus + chronic idiopathic neck pain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic tinnitus only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic idiopathic neck pain only
Number of subjects: 0
Study: 37616289

Group type: EXPERIMENTAL
Intervention: A7+TouchCare insulin patch pump system
Number of subjects: 100

Group type: COMPARATOR
Intervention: Omnipod insulin pump system
Number of subjects: 100
Study: 37616301

Group type: EXPERIMENTAL
Intervention: Moxidectin (MOX) 8 mg plus DEC and ALB
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Moxidectin (MOX) plus ALB
Number of subjects: 58

Group type: COMPARATOR
Intervention: Ivermectin (IVM) 0.2 mg/kg plus DEC 6 mg/kg and ALB 400 mg
Number of subjects: 58

Group type: COMPARATOR
Intervention: Ivermectin (IVM) plus ALB
Number of subjects: 58
Study: 37616393

Group type: EXPERIMENTAL
Intervention: Routine point-of-care capillary blood ketone measurements
Number of subjects: 484

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 484
Study: 37616463

Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis (PD)
Number of subjects: 0
Study: 37616485

Group type: EXPERIMENTAL
Intervention: Early onset delirium during hospitalization
Number of subjects: 0
Study: 37616531

Group type: EXPERIMENTAL
Intervention: Print intervention
Number of subjects: 298

Group type: COMPARATOR
Intervention: Web intervention
Number of subjects: 298
Study: 37616583

Group type: EXPERIMENTAL
Intervention: Fully closed-loop with ultrarapid insulin lispro (CamAPS HX system)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Insulin pump therapy with continuous glucose monitoring (CGM)
Number of subjects: 26
Study: 37616588

Group type: EXPERIMENTAL
Intervention: 1km-TWT (1-km treadmill walking test)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 1km-TWT
Number of subjects: 64
Study: 37619218

Group type: EXPERIMENTAL
Intervention: Higher-protein-RUTF
Number of subjects: 0
Study: 37619252

Group type: COMPARATOR
Intervention: Estrogen alone
Number of subjects: 23299

Group type: COMPARATOR
Intervention: Estrogen combined with progestogens
Number of subjects: 23299

Group type: COMPARATOR
Intervention: Synthetic steroids
Number of subjects: 23299

Group type: COMPARATOR
Intervention: SERMs
Number of subjects: 23299

Group type: COMPARATOR
Intervention: SERMs combined with estrogen
Number of subjects: 23299
Study: 37619443

Group type: EXPERIMENTAL
Intervention: Danish Drowning Formula
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Drowning-related OHCA at swimming pools
Number of subjects: 374
Study: 37619579

Group type: EXPERIMENTAL
Intervention: Adjuvant oral mitotane (two or three times daily, target plasma concentration of 14-20 mg/L) for 2 years
Number of subjects: 91

Group type: COMPARATOR
Intervention: Surveillance alone
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Adjuvant oral mitotane
Number of subjects: 91
Study: 37619584

Group type: EXPERIMENTAL
Intervention: IBIO123 (1 mg, 5 mg, or 10 mg)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: IBIO123 (10 mg)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: IBIO123
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 37619651

Group type: EXPERIMENTAL
Intervention: Black participants
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Greater neighborhood deprivation
Number of subjects: 54
Study: 37619656

Group type: EXPERIMENTAL
Intervention: Two-fraction SABR (26 Gy to the prostate +/- 32 Gy boost)
Number of subjects: 60
Study: 37619705

Group type: EXPERIMENTAL
Intervention: Combination of acetaminophen and ibuprofen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acetaminophen and hydrocodone
Number of subjects: 0
Study: 37619779

Group type: EXPERIMENTAL
Intervention: Tezepelumab 210 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37619861

Group type: EXPERIMENTAL
Intervention: Dichoptic treatment
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dichoptic treatment with additional treatment for residual amblyopia
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dichoptic treatment without additional treatment for residual amblyopia
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dichoptic treatment (no additional treatment)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Patching and atropine
Number of subjects: 100
Study: 37619976

Group type: EXPERIMENTAL
Intervention: Contemporary drug-eluting stents in patients with premature CAD
Number of subjects: 3323
Study: 37619980

Group type: EXPERIMENTAL
Intervention: SGN-B6A (antibody-drug conjugate directed to integrin beta-6)
Number of subjects: 0
Study: 37620152

Group type: EXPERIMENTAL
Intervention: GDF-15 levels at admission
Number of subjects: 6322
Study: 37620255

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Retrospective cohort from 2019
Number of subjects: 0
Study: 37620260

Group type: EXPERIMENTAL
Intervention: Infusion of argipressin
Number of subjects: 248

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 248
Study: 37620263

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bidimensional (2D) Doppler ultrasound
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: MicroVascular Flow technique
Number of subjects: 30
Study: 37620270

Group type: EXPERIMENTAL
Intervention: Automated clinical decision support tool for intraoperative insulin dosing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard insulin administration (control)
Number of subjects: 0
Study: 37620277

Group type: EXPERIMENTAL
Intervention: Training of volunteers in new technologies and volunteer accompaniment of patients/relatives using technologies
Number of subjects: 70

Group type: COMPARATOR
Intervention: Usual accompaniment of patients
Number of subjects: 70
Study: 37620294

Group type: EXPERIMENTAL
Intervention: High-carbohydrate fluid diet (CFD) - 400 mL of maltodextrin orally 2 h before ERCP
Number of subjects: 1330

Group type: COMPARATOR
Intervention: Fasting group - abstained from food/water overnight (>6 h) before ERCP
Number of subjects: 1330
Study: 37620412

Group type: EXPERIMENTAL
Intervention: Intraoperative abnormal Neurological pupil index (NPi)
Number of subjects: 123
Study: 37620508

Group type: EXPERIMENTAL
Intervention: EGCG solution (epigallocatechin-3-gallate)
Number of subjects: 19
Study: 37620507

Group type: EXPERIMENTAL
Intervention: Average cluster size from the point process model
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Spatial clustering measures
Number of subjects: 587
Study: 37620627

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (nivo+ipi)
Number of subjects: 64
Study: 37620730

Group type: EXPERIMENTAL
Intervention: Plasma prolactin levels in NMOSD patients
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Macroprolactinemia in NMOSD patients
Number of subjects: 19
Study: 37620760

Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment (CGA) delivered by Advanced Nursing Practitioners (ANPs)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 72
Study: 37620807

Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37620825

Group type: EXPERIMENTAL
Intervention: Active tDCS (n=21)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sham stimulation (n=17)
Number of subjects: 38
Study: 37620855

Group type: EXPERIMENTAL
Intervention: Drug Resistance Mutation (DRM) testing
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Decentralized DRM testing process
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Implementation of DRM testing
Number of subjects: 68
Study: 37620858

Group type: EXPERIMENTAL
Intervention: C18:1AC exposure
Number of subjects: 0
Study: 37620921

Group type: EXPERIMENTAL
Intervention: Computer-aided detection (CAD4TB v7)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: C-reactive protein (Alere Afinion)
Number of subjects: 4
Study: 37620929

Group type: EXPERIMENTAL
Intervention: SMART intervention (twice weekly football, martial arts, and dance coaching)
Number of subjects: 664

Group type: COMPARATOR
Intervention: Control group (sport as usual)
Number of subjects: 664
Study: 37620974

Group type: EXPERIMENTAL
Intervention: Postoperative glycemic variability (measured by coefficient of variability of blood glucose within 24 hours)
Number of subjects: 177
Study: 37621153

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg/day
Number of subjects: 6799

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6799

Group type: EXPERIMENTAL
Intervention: Empagliflozin (after withdrawal for ≈30 days)
Number of subjects: 6799

Group type: COMPARATOR
Intervention: Placebo (after withdrawal for ≈30 days)
Number of subjects: 6799

Group type: EXPERIMENTAL
Intervention: Empagliflozin (change in risk after withdrawal)
Number of subjects: 6799
Study: 37621406

Group type: EXPERIMENTAL
Intervention: Neoadjuvant nivolumab, ipilimumab, and intratumor talimogene laherparepvec (T-VEC)
Number of subjects: 6
Study: 37621674

Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg daily for 7 days, followed by 5 mg/kg daily for 7 days)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Azithromycin among participants receiving other antibiotics
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Azithromycin among antibiotic-naïve participants
Number of subjects: 200
Study: 37621686

Group type: EXPERIMENTAL
Intervention: Axillary radiotherapy (ART) without axillary lymph node dissection (ALND)
Number of subjects: 1660

Group type: COMPARATOR
Intervention: Axillary lymph node dissection (ALND)
Number of subjects: 1660

Group type: EXPERIMENTAL
Intervention: Axillary radiotherapy (ART)
Number of subjects: 1660
Study: 37621688

Group type: EXPERIMENTAL
Intervention: Neratinib plus capecitabine (N+C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lapatinib plus capecitabine (L+C)
Number of subjects: 0
Study: 37621919

Group type: EXPERIMENTAL
Intervention: Vaccinated participants
Number of subjects: 2167

Group type: COMPARATOR
Intervention: Phase 1 (November-December 2020)
Number of subjects: 2167

Group type: EXPERIMENTAL
Intervention: Phase 2 (November-December 2021)
Number of subjects: 2167

Group type: EXPERIMENTAL
Intervention: Longitudinal analysis at 6 and 12 months
Number of subjects: 2167